Lonza to make trial stocks of Micromet cancer MAb

By Staff Reporter

- Last updated on GMT

Related tags: Leukemia

Lonza will produce trial supplies of Micromet’s candidate blood cancer treatment blinatumomab under a contract announced today.

The Swiss contractor will undertake process development and manufacturing of the monoclonal antibody (MAb), which is in trials for both acute lymphoblastic leukemia and non-Hodgkin’s lymphoma.

Maryland, US headquartered Micromet can also ask Lonza to develop commercial-scale manufacturing processes for the antibody if it goes on to gain regulatory approval.

Micromet, which reacquired rights to commericalise blinatumomab from AstraZeneca’s MedImmune arm earlier this month, developed the MAb using its BiTE development platform.

The technology, which stimulates the body's cytotoxic, or cell-destroying, T cells against tumor cells, is also the subject of collaborations with Bayer Schering Pharma, Nycomed and Merck Serono.

Most recently Micromet signed a $475m deal with French drugmaker Sanofi-Aventis that will see the US developer use its technology to develop another anticancer antibody through to Phase II clinical trials.

At the time Sanofi's senior VP of R&D, Marc Cluzel, said: “Micromet's BiTE antibodies represent a promising new approach to treating cancer," adding that “we believe [they] have the potential to significantly expand the treatment options that we can offer to cancer patients in the future​."

Lonza biomanufacturing

Earlier this month Lonza’s biomanufacturing arm won another MAb deal signing with GlaxoSmithKline (GSK) and Genmab’s to make Arzerra (ofatumumab) on a commercial-scale.

Arzerra, which was recently approved by the US Food and Drug Administration (FDA) for chronic lymphocytic leukemia (CLL), was described as a “key biopharmaceutical for both [GSK and Genmab],” ​by Lonza COO Stephan Kutzer.

That deal, coupled with the new Micromet accord, may indicate that Lonza’s biomanufacturing arm is emerging as one of the “go to” contract manufacturing solutions for the large-scale production of biologics.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars